	US 11,753,406 B2
	Salts of a PD-1/PD-L1 inhibitor
Zhongjiang Jia, Kennett Square, PA (US); Pingli Liu, Wilmington, DE (US); David J. Meloni, Bear, DE (US); Yongchun Pan, Wilmington, DE (US); Yongzhong Wu, Glen Mills, PA (US); Jiacheng Zhou, Newark, DE (US); and Qun Li, Newark, DE (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Aug. 7, 2020, as Appl. No. 16/987,557.
Claims priority of provisional application 62/884,996, filed on Aug. 9, 2019.
Prior Publication US 2021/0040090 A1, Feb. 11, 2021
Int. Cl. C07D 471/04 (2006.01); A61K 9/00 (2006.01)

CPC C07D 471/04 (2013.01) [A61K 9/0053 (2013.01); C07B 2200/13 (2013.01)]

23 Claims

1. A salt, wherein the salt is

(R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid di-oxalic acid salt, and wherein the salt is crystalline.